LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 204 filers reported holding LIGAND PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,591,884 | -29.4% | 360,345 | -15.0% | 1.01% | -26.7% |
| Q2 2023 | $30,571,784 | -7.5% | 424,019 | -5.7% | 1.38% | -16.2% |
| Q1 2023 | $33,065,822 | +55.1% | 449,508 | +40.9% | 1.64% | +39.5% |
| Q4 2022 | $21,312,820 | -46.1% | 319,054 | -30.5% | 1.18% | -48.5% |
| Q3 2022 | $39,552,000 | -1.1% | 459,315 | +2.4% | 2.29% | +3.5% |
| Q2 2022 | $40,003,000 | -27.7% | 448,363 | -8.8% | 2.21% | -7.2% |
| Q1 2022 | $55,313,000 | -18.0% | 491,717 | +12.7% | 2.38% | -5.1% |
| Q4 2021 | $67,415,000 | +9.9% | 436,456 | -0.9% | 2.51% | +7.9% |
| Q3 2021 | $61,340,000 | +1.9% | 440,283 | -4.1% | 2.33% | -1.1% |
| Q2 2021 | $60,210,000 | -12.0% | 458,955 | +2.3% | 2.35% | -18.5% |
| Q1 2021 | $68,395,000 | +106.6% | 448,637 | +34.8% | 2.89% | +95.2% |
| Q4 2020 | $33,102,000 | -28.5% | 332,854 | -31.5% | 1.48% | -37.9% |
| Q3 2020 | $46,310,000 | +54.1% | 485,842 | +80.8% | 2.38% | +36.7% |
| Q2 2020 | $30,061,000 | – | 268,761 | – | 1.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KNOTT DAVID M | 353,041 | $36,819,000 | 14.92% |
| CARDINAL CAPITAL MANAGEMENT LLC /CT | 919,994 | $95,946,000 | 2.93% |
| Elk Creek Partners, LLC | 236,862 | $24,702,000 | 2.84% |
| Conestoga Capital Advisors, LLC | 619,653 | $64,624,000 | 1.56% |
| WOODSTOCK CORP | 71,489 | $7,456,000 | 1.21% |
| Summit Creek Advisors LLC | 70,962 | $7,401,000 | 1.16% |
| FALCON POINT CAPITAL, LLC | 8,115 | $846,000 | 1.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 302,503 | $31,548,000 | 1.07% |
| Stephens Investment Management Group LLC | 508,100 | $52,990,000 | 1.00% |
| Tygh Capital Management, Inc. | 55,672 | $5,806,000 | 0.96% |